Clinical Trials Logo

Epstein-Barr Virus Infections clinical trials

View clinical trials related to Epstein-Barr Virus Infections.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06002802 Completed - Clinical trials for Epstein-Barr Virus Infections

Study on Infectious Mononucleosis in Munich

IMMUC
Start date: March 1, 2016
Phase:
Study type: Observational

This observational clinical study aims at the identification of novel biomarkers and causative factors of complicated and/or protracted Epstein-Barr virus-associated infectious mononucleosis (IM). Clinical, biochemical, and routine virological data were collected from 200 patients with IM, novel analytical tools were implemented, and immunological and virological experimental data were generated using blood samples and mouthwashes. Patients have been investigated within four weeks after the onset of symptoms as well as one month and six months thereafter.

NCT ID: NCT05604378 Completed - Gastric Cancer Clinical Trials

Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis

Start date: August 3, 2022
Phase:
Study type: Observational

The data of 460 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection between January 2017 and February 2022 were analyzed. The clinicopathological features and prognosis of the patients with EBV-positive gastric cancers were compared with those of EBV-negative gastric cancers. Immunohistochemistry for epidermal growth factor receptor (EGFR), C-erb B2, Ki-67, and p53 was performed. Additionally, in situ hybridization was conducted to detect EBV, and microsatellite instability (MSI) analysis was used to assess the deficiency in mismatch repair (MMR) genes.

NCT ID: NCT05535569 Completed - Clinical trials for Recurrent/Metastatic Gastric Cancer

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

Start date: July 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II study to identify the recommended dose of paclitaxel and nivolumab for further study, and to assess the safety and clinical efficacy of this combined treatment in EBV-related, MSI-high, or PD-L1 positive advanced gastric cancer after first line treatment.

NCT ID: NCT04693637 Completed - Clinical trials for Cytomegalovirus Infections

Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Prevent
Start date: January 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.

NCT ID: NCT03546101 Completed - Clinical trials for Post-transplant Lymphoproliferative Disorder

Early Detection of Epstein-Barr Virus Related Disease.

Start date: November 1, 2017
Phase:
Study type: Observational

Epstein-Barr virus (EBV) is one of several herpesviruses that cause disease in humans. EBV virus has an oncogenic potential, and it has been associated with the development of a wide range of cancers. Previous studies have shown a close association between EBV and Post-Transplant Lymphoproliferative disorder (PTLD) in transplant recipients. As part of a preventive approach against PTLD, several transplantation units now monitor the occurrence of EBV-DNAemia after transplantation. However, there is little evidence to guide this strategy; nor is there consensus concerning either the best specimen to use for EBV analysis (whole blood or plasma). In this study investigators aim to optimise and validate a polymerase chain reaction (PCR)-test for EBV-DNA on, respectively, whole blood, plasma and a combination of plasma and lymphocytes. The investigators wish to determine which of the three tests best predicts current and future risk of development of EBV-related diseases such as mononucleosis and PTLD.

NCT ID: NCT03397706 Completed - Clinical trials for Lymphoproliferative Disorders

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Start date: March 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory EBV+ lymphomas.

NCT ID: NCT03374566 Completed - Clinical trials for Epstein-Barr Virus Infections

Immunodeficiency for Severe Epstein-Barr Virus Infection

Start date: December 1, 2017
Phase:
Study type: Observational

The purpose of this study is to investigate the immune responses associated with Epstein-Barr virus infections, and to find out the possible immunodeficiency that may be linked to severe Epstein-Barr virus infections.

NCT ID: NCT02715752 Completed - Clinical trials for Cytomegalovirus Infections

A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Start date: January 2016
Phase: N/A
Study type: Observational

This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

NCT ID: NCT02499302 Completed - Clinical trials for Fatigue Syndrome, Chronic

Mental Training for CFS Following EBV Infection in Adolescents

Start date: October 2015
Phase: N/A
Study type: Interventional

The general aim of this study is to investigate the effect of an individually tailored mental training program in adolescents developing chronic fatigue syndrome (CFS) after an acute Epstein Barr-virus (EBV) infection. Endpoints include physical activity (primary endpoint), symptoms (fatigue, pain, insomnia), cognitive function (executive functions) and markers of disease mechanisms (autonomic, endocrine, and immune responses).

NCT ID: NCT02335437 Completed - Clinical trials for Fatigue Syndrome, Chronic

Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents

CEBA
Start date: March 2015
Phase: N/A
Study type: Observational

Chronic fatigue syndrome (CFS) is characterized by unexplained, disabling and long lasting fatigue, as well as pain, impaired memory, sleep difficulties and other symptoms. Epstein-Barr virus (EBV) infection might precipitate CFS. In this study, 200 adolescents undergoing acute EBV infection will be followed prospectively, and also compared with a group of healthy controls. The aim is twofold: - To identify factors that predispose to chronic fatigue among adolescents with acute EBV infection - To compare pathophysiological features of patients with acute EBV infection with a group of healthy controls. Possible risk factors for chronic fatigue 6 months after EBV-infection includes: - Severity of the initial infection - Immune responses characteristics - Characteristics of the neuroendocrine stress response - Cognitive functioning - Emotional disturbances - Genetics/ epigenetics of candidate genes - Certain personality traits - Critical life events